Author

Fiona Carlin

Browsing

In Brief In a judgment of 18 October 2023 (T-74/21), the EU’s General Court roundly dismissed the appeal by Teva and Cephalon against the European Commission’s 2020 decision imposing fines of approximately €30 million on each of them for concluding an anti-competitive patent settlement agreement back in 2005. In some ways the case is an historic relic: since the US Supreme Court’s 2013 ruling in Actavis and the Commission’s decision a few days later in…

In Brief 2023 is gearing up to be an interesting year for those in the life sciences sector, with upcoming reforms to the established regulatory and IP landscapes that will impact innovator strategies in R&D, commercialisation, and patent enforcement. While reforms are currently under draft by the European Commission, the key areas of anticipated change are highlighted in a newly published article in The Life Sciences Lawyer. “EU reforms in the pharmaceutical sector – a…

The European Court of Justice (the “Court”) has upheld the lawfulness of a Latvian law banning any advertising of medicinal products to the general public that encourages purchases by offering discounts and other special price offers, including reduced bundled pricing. The Court goes as far as saying that Member States must ban such advertising, even if not expressly prohibited by EU harmonising rules, where that is necessary to prevent the irrational use of medicines that…